ConductScreen
Combinatorial Integration

Multi-Modal Integration

Why combination of orthogonal measurement dimensions beats any single endpoint for developmental neurotoxicity detection

Three Orthogonal Measurement Dimensions

PCA on 9 morphological features (N=64 organoids) reveals 3 independent dimensions capturing 99.4% of total variance.

PC1-Size

71.9%

Overall organoid size, dominated by area, perimeter, and axis measurements. Captures proliferative capacity and growth rate differences.

Top loadings

+0.39minor_axis_um
+0.38equiv_diameter_um
+0.37area_um2

Discriminates

A1Aq=<.001B2Aq=<.001TH2q=<.001

PC2-Asymmetry

19.4%

Shape asymmetry and directional growth bias. Captures cytoskeletal polarity and tissue architecture disruption.

Top loadings

+0.51elongation
-0.51eccentricity
-0.34major_axis_um

Discriminates

B2Aq=0.042

PC3-Roundness

8.2%

Tissue organization quality and structural integrity. Captures self-assembly quality and boundary regularity.

Top loadings

+0.59solidity
+0.54circularity
+0.45eccentricity

Discriminates

A1Aq=0.038B2Aq=0.001TH2q=0.021

Single vs. Multi-Modal Detection

Each PCA composite detects a different subset of clones. Combining all three ensures no disease model escapes detection.

PC1 alone
3/3
PC2 alone
1/3
PC3 alone
3/3
≥2 PCs concordant
3/3

False Positive Rate Reduction

Requiring concordance across independent composites exponentially reduces false positive rates.

15.0%

Single composite

1 composite required

2.3%

Two concordant

2 composites required

0.3%

Three concordant

3 composites required

Under independence assumption: P(concordant false positive) = (single FPR)^n. Single composite FPR \u2248 15% (Bonferroni-adjusted threshold). Two concordant: 0.15² = 2.3%. Three concordant: 0.15³ = 0.3%.

Pass / Flag / Fail Classifier

Toggle between single-modal (PC1 only) and multi-modal (all 3 PCs) to see how combinatorial analysis improves classification confidence.

Pass:0 composites significant
Flag:1 composite significant
Fail:≥2 composites significant
wt2D
Pass

Wildtype Control

PC1
PC2
PC3

0 composites flagged

A1A
Fail

TUBA1A Mutant

PC1
PC2
PC3

2 composites flagged

B2A
Fail

TUBB2A Mutant

PC1
PC2
PC3

3 composites flagged

TH2
Fail

TH Deficient

PC1
PC2
PC3

2 composites flagged

Multi-modal analysis: Combining 3 orthogonal composites, all disease clones are classified as “Fail” (≥2 composites significant) while wildtype remains “Pass.” Cross-modal confirmation reduces false positive rate from 15% to 2.3%.

Principle Validated in Regulatory Science

The multi-endpoint integration strategy is not novel to ConductScreen — it is the established approach in regulatory toxicology. EPA's integrated DNT battery achieved 93% sensitivity by combining multiple NAM endpoints (Carstens et al. 2022, Alternatives to Laboratory Animals). ConductScreen applies this same principle within a single automated workflow: multiple orthogonal morphological composites provide cross-modal confirmation that no single endpoint can achieve alone.

Phase 2 Expansion

Phase 2 adds two additional orthogonal measurement dimensions, further reducing false positive rates:

Temporal Module

Growth trajectory composites add time-series dynamics as a 4th orthogonal dimension

Boundary Module

Neurite topology composites add structural connectivity as a 5th orthogonal dimension

With 5 orthogonal composites: P(concordant false positive) = 0.15&sup5; = 0.0076% — approaching zero false positive risk for ≥2 concordant composites.